IL157498A0 - Vaccine - Google Patents

Vaccine

Info

Publication number
IL157498A0
IL157498A0 IL15749802A IL15749802A IL157498A0 IL 157498 A0 IL157498 A0 IL 157498A0 IL 15749802 A IL15749802 A IL 15749802A IL 15749802 A IL15749802 A IL 15749802A IL 157498 A0 IL157498 A0 IL 157498A0
Authority
IL
Israel
Prior art keywords
vaccine
Prior art date
Application number
IL15749802A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL157498A0 publication Critical patent/IL157498A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5406IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5437IL-13
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15749802A 2001-03-03 2002-03-01 Vaccine IL157498A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens
PCT/GB2002/000900 WO2002070711A1 (en) 2001-03-03 2002-03-01 Vaccine

Publications (1)

Publication Number Publication Date
IL157498A0 true IL157498A0 (en) 2004-03-28

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15749802A IL157498A0 (en) 2001-03-03 2002-03-01 Vaccine

Country Status (18)

Country Link
US (3) US20050260216A1 (no)
EP (1) EP1368477A1 (no)
JP (1) JP4238031B2 (no)
KR (1) KR20030081490A (no)
CN (1) CN1543504A (no)
AU (1) AU2002233560B2 (no)
BR (1) BR0207819A (no)
CA (1) CA2439628A1 (no)
CZ (1) CZ20032373A3 (no)
GB (1) GB0105360D0 (no)
HU (1) HUP0303372A3 (no)
IL (1) IL157498A0 (no)
MX (1) MXPA03007915A (no)
NO (1) NO20033882L (no)
NZ (1) NZ527873A (no)
PL (1) PL365066A1 (no)
WO (1) WO2002070711A1 (no)
ZA (1) ZA200306647B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510282A (ja) * 1999-09-25 2003-03-18 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫刺激核酸
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
AR041086A1 (es) * 2002-08-30 2005-04-27 Glaxo Group Ltd Vacuna
WO2004019979A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Vaccine comprising il-13 and an adjuvant
AU2003263150A1 (en) * 2002-09-12 2004-04-30 Pharmexa A/S Immunization against autologous ghrelin
US9243064B2 (en) * 2003-01-31 2016-01-26 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2004084837A2 (en) * 2003-03-24 2004-10-07 Mercia Pharma Llc Methods and compositions for treating and preventing inflammatory conditions
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
CN1997395B (zh) * 2004-06-11 2012-08-29 独立行政法人理化学研究所 含有包含在脂质体中的调节性细胞配体的药物
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP2010527916A (ja) * 2007-04-23 2010-08-19 ワイス・エルエルシー Il−13関連障害を治療する方法および組成物ならびにその治療をモニターする方法
JP2010527633A (ja) * 2007-05-25 2010-08-19 セントコア・オーソ・バイオテツク・インコーポレーテツド Toll様受容体3モジュレーター及びその使用
EA026990B1 (ru) * 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR20230137385A (ko) * 2021-01-29 2023-10-04 바이엘 애니멀 헬스 게엠베하 자기-관용을 파괴하기 위한 백신 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
EP0772619B2 (en) * 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
CA2196200A1 (en) * 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
CA2213301C (en) * 1995-02-20 2010-01-26 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー, インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
AU758265B2 (en) * 1998-03-20 2003-03-20 Genzyme Corporation Induction of immunity against tumor self-antigens
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
AU5617900A (en) * 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses

Also Published As

Publication number Publication date
NO20033882D0 (no) 2003-09-02
JP2005502314A (ja) 2005-01-27
JP4238031B2 (ja) 2009-03-11
NO20033882L (no) 2003-10-31
NZ527873A (en) 2005-12-23
BR0207819A (pt) 2004-03-02
HUP0303372A3 (en) 2008-06-30
CZ20032373A3 (cs) 2004-01-14
EP1368477A1 (en) 2003-12-10
CA2439628A1 (en) 2002-09-12
US20030194391A1 (en) 2003-10-16
GB0105360D0 (en) 2001-04-18
KR20030081490A (ko) 2003-10-17
HUP0303372A2 (hu) 2004-01-28
ZA200306647B (en) 2004-11-26
US20050260216A1 (en) 2005-11-24
CN1543504A (zh) 2004-11-03
AU2002233560B2 (en) 2006-09-07
US20050186209A1 (en) 2005-08-25
PL365066A1 (en) 2004-12-27
MXPA03007915A (es) 2003-12-04
WO2002070711A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
HUP0402471A3 (en) Vaccine
IL227966A0 (en) Vaccination kit
GB0103170D0 (en) Vaccine composition
GB0103171D0 (en) Vaccine composition
GB0407935D0 (en) Vaccine
HUP0402259A3 (en) Vaccines
IL157498A0 (en) Vaccine
EP1423141A4 (en) VACCINE
GB0306611D0 (en) Novel vaccine
AU1591402A (en) Vaccine
GB0121171D0 (en) Vaccine
GB0014288D0 (en) Vaccine
GB0014845D0 (en) Vaccine
GB0105238D0 (en) Vaccines
GB0003082D0 (en) Vaccine
GB0006693D0 (en) Vaccine
GB0015722D0 (en) Vaccine
GB0106589D0 (en) Vaccine
GB0124137D0 (en) Vaccine
GB0115496D0 (en) Vaccine
GB0130823D0 (en) Vaccine
GB0128312D0 (en) Vaccine
GB0103867D0 (en) Vaccine
GB0104542D0 (en) Novel vaccine
GB0107511D0 (en) Novel vaccine